Jerry Sullivan is editor of the Business Journal. He directs the paper's coverage and layout and oversees a team of award-winning reporters. He also oversees the paper's website. He can be reached at email@example.com.
The Insider isn’t ready to make a flat-out prediction but will say this much on the latest turn in the Allergan-Valeant saga: It looks as though David Pyott can play for a tie while his opponents have to win—and do it in regulation time.
Sheril Liu of ReMax Premier Realty in Irvine put a clear focus on one of the ways the city—with a population a bit under 250,000—punches above its weight.
There’s been much consternation about the relatively slow pace of employment growth nationally, even with last week’s report of a big gain on jobs in June.
Here’s one way to look at things as the dust settles on last week’s action in the hostile bid for Allergan by Valeant Pharmaceuticals and Pershing Square’s Bill Ackman: Allergan boss David Pyott’s less-is-more approach on PR tops the raiders’ tendency to work the press at each turn of the drama.
How did the multibillionaire Koch brothers raise $60 million over lunch last week at the Ritz-Carlton in Dana Point?
President Barack Obama was getting close to OC as the Insider went to press, carrying the promise of plenty of memories for UCI grads set to hear his commencement address at Angel Stadium.
Look who’s feeling fresh in brand-new digs—Bill Gross, who joined the rest of the Pimco crew for hot dogs and burgers on the porch of their recently completed HQ in Newport Center last week.
The Insider notes changes in Michael Pearson’s vocabulary as Valeant’s hostile bid for Allergan wears on—and perhaps a new tone altogether in his pronouncement last week that he won’t “overpay” to get the deal done.
Here’s one perspective on Allergan as it attempts to fend off a hostile $47 billion bid by Valeant Pharmaceuticals: The drug maker could be lost to its hometown despite a laundry list of things that both have done right when it comes to fostering the company’s growth since it moved from L.A. to Irvine in the early 1970s.
This week’s Special Issue features the OC 50, our annual inventory of influence, which has included David Pyott ever since 1998, shortly after he signed on as CEO of Allergan Inc.